Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development

Drug Discovery & Development

Visterra, A*STAR to develop monoclonal antibody VIS513 to treat dengue By PBR Staff Writer
US-based biotechnology firm Visterra and the Drug Discovery & Development (D3) unit under the Agency for Science, Technology and Research (A*STAR), Singapore, have collaborated to further the development of VIS513, Visterra’s neutralizing antibody to treat dengue fever.
Drug Research > Drug Discovery & Development > News
R-Tech Ueno completes Phase I single-dose trial for new VAP-1 Inhibitor RTU-1096 By PBR Staff Writer
Japan-based pharmaceutical venture business R-Tech Ueno has completed the Phase I single-dose clinical trial for the new molecular entity RTU-1096, a vascular adhesion protein-1 (VAP-1) inhibitor having anti-inflammatory and immunomodulatory effects.
Drug Research > Drug Discovery & Development > News Regeneron, Sanofi report positive topline results from Phase III trials with sarilumab in patients with rheumatoid arthritis Regeneron Pharmaceuticals, and Sanofi announced that a Phase 3 study of sarilumab, an investigational, fully human IL-6 receptor antibody, met its co-primary efficacy endpoints of a greater improvement in signs and symptoms of rheumatoid arthritis (RA) at 24 weeks and physical function at 12 weeks, compared to placebo.
Drug Research > Drug Discovery & Development > News
See more Drug Discovery & Development news

Latest Drug Discovery & Development News and Insight

View all Drug Discovery & Development news or find news targeted to your interests
Growing Potential: mAb Production With Fibra-Cel
| By Eppendorf
The market for monoclonal antibodies continues to grow steadily, but there are still bottlenecks in the development of new products, including long development times mostly due to R&D. Advanced bioprocess equipment that meets the specific demands of mAb-producing hybridoma can accelerate design and production, and reduce overall development costs along the way.
Drug Research > Drug Discovery & Development > White Papers
DoE Bioprocess Development
| By Eppendorf
Eppendorf DASware is the effective route to design of experiments (DoE) in early-stage bioprocess development. Claudia M Huether-Franken and Sebastian Kleebank explain how the design software applies DoE to DASGIP parallel bioreactor systems.
Drug Research > Drug Discovery & Development > White Papers
Taking the Strain
| By Eppendorf
Today, the rapidly expanding demand for vaccine products for viral diseases such as rabies has necessitated the development of more sophisticated production techniques based around cell culture systems. This article reviews vaccine production strategies, with a focus on rabies, looking specifically at the use of the Vero cell line - used worldwide and approved by the US Food and Drug Administration - as well as media technology and the bioreactor options available.
Drug Research > Drug Discovery & Development > White Papers
SignalRx gets STTR grant from NIH to develop dual PI3 kinase/bromodomain inhibitors as anticancer agents
SignalRx Pharmaceuticals, focused on developing more effective oncology drugs though molecular design imparting selective multiple target inhibition, announced that it has received non-dilutive funding to advance the preclinical development of unique small molecule inhibitors designed to inhibit multiple critical cancer targets.
Drug Research > Drug Discovery & Development > News
Faron, China Medical System to develop traumakine to treat ARDS
By PBR Staff Writer
Finnish biopharmaceutical firm Faron, China Medical Systems (CMS) and A&B have entered into a strategic agreement to develop and commercialize traumakine to treat moderate to severe acute respiratory distress syndrome (ARDS).
Drug Research > Drug Discovery & Development > News
Designing Wellness for Fun and Satisfaction: Gummies - Based Nutrition
| By Softigel pbr
The gummy delivery form for vitamins, minerals and supplements is the single-largest source of growth among the supplements category. Vitamin users report preference for gummy/soft chewable products because these offer not only pleasure and a fun experience, but efficacy and convenience. The selection of materials during the design process of the formula is critical for the final product in order to meet the expectations of the consumers, which is to find a healthy product that will give them a delicious reward as well. Based on the design and development process, this paper reviews review in detail the stage of selection of materials and validation as a critical phase to obtain a product that represents quality and stability as well as the specific requirements of the costumers and the consumers.
Drug Research > Drug Discovery & Development > White Papers
RadioMedix, Areva Med to develop new treatment against NETs
By PBR Staff Writer
US-based biotechnology firm RadioMedix has entered into an agreement with Areva Med to jointly develop a new treatment against neuroendocrine tumors (NETs) using Targeted Alpha Therapy with lead-212 (212Pb).
Drug Research > Drug Discovery & Development > News
Roche reports positive interim results from Phase II trial of MPDL3280A
Roche announced interim results from a global, randomised Phase II study (POPLAR) in people with previously treated NSCLC.
Drug Research > Drug Discovery & Development > News
Fibromyalgia treatment market value will crawl to $1.9bn by 2023, says GlobalData
The treatment market value for fibromyalgia across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, will expand from $1.8 billion in 2013 at a tepid Compound Annual Growth Rate (CAGR) of 0.72% to reach $1.9 billion by 2023, according to research and consulting firm GlobalData.
Drug Research > Drug Discovery & Development > News
D-Pharm gets final report for Phase II trial of THR-18 in acute stroke patients treated With tPA
D-Pharm has received the final report for its Phase 2 clinical study of THR-18. THR-18 demonstrated statistically significant reductions in the incidence of intracranial hemorrhage (ICH), brain swelling (edema) and a satisfactory safety profile in stroke patients treated with tPA.
Drug Research > Drug Discovery & Development > News
View all Drug Discovery & Development news or find news targeted to your interests